About this trial
Strategies for invasive intervention in acute pancreatitis include sequential or combined use of multiple drainage and debridement modalities. The more widely used is the step-up approach, which requires an individualized and multidisciplinary (internal medicine, interventional radiology, endoscopy, surgery, critical care medicine, and nutritionists) approach. The available evidence from randomized controlled studies is from highly selected subject populations, and it is unclear whether the results can be applied to complex clinical situations in real clinics, and the optimal strategy for drainage of peripancreatic lesions in different patients still needs to be evaluated in the real world. This study intends to establish a prospective single-center cohort for real-world analysis to collect comprehensive clinic information and clinical outcomes, to evaluate the effectiveness and safety of existing intervention strategies, especially the timing and modality of interventions, in real-world clinical practice, and to explore the key factors affecting patient prognosis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Admission diagnosis of acute pancreatitis;
Localized complications confirmed by imaging examinations;
Voluntary participation in the study and signing of an informed consent form.
Disqualifiers
Improved with conservative treatment without invasive interventions for local complications during hospitalization.
Trial population
Hospitalized acute pancreatitis patients requiring invasive interventions.
Trial design
Cohort
Prospective
Treatments tested in this trial
Invasive intervention for acute pancreatitis
Procedure/SurgeryInvasive interventions include drainage (endoscopic transmural drainage, imaging-guided percutaneous catheter drainage) and debridement (endoscopic debridement, videoscopic assisted retroperitoneal debridement, laparoscopic surgical debridement, open surgical debridement).
Treatment groups
Trial outcomes
Primary outcomes
Major complications or death
A composite of major complications (i.e., new-onset multiple organ failure or systemic complications, enterocutaneous fistula or perforation of a visceral organ requiring intervention, or intraabdominal bleeding requiring intervention) or death during admission or during the 6 months after discharge.
Secondary outcomes
Organ failure
New-onset ( not present at any time in the 24 hours before first intervention) pulmonary failure, circulatory failure, or renal failure
Systemic complication
New-onset ( not present at any time in the 24 hours before first intervention) systematic complications such as disseminated intravascular coagulation, severe metabolic disturbance, and gastrointestinal bleeding
Enterocutaneous fistula
Secretion of fecal material from a percutaneous drain or drainage canal after removal of drains or from a surgical wound, either from small or large bowel; confirmed by imaging or during surgery
Perforation of visceral organ
Perforation requiring surgical, radiologic, or endoscopic intervention
Sponsors and contacts
Click on the lead sponsor to view all of their trials.